whatshot

RLAY   $9.91  -0.90% Market Closed After Close 9.69 -2.22%

Relay Therapeutics, Inc.
show_chart Advanced Chart of RLAY
Last Events:

2024-02-26 The hottest instrument.

2024-02-25 The hottest instrument.

2024-02-24 The hottest instrument.

2023-08-09 Signal in RSI changed from bearish weakening to bearish recovery. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.

2023-08-06 Signal in RSI changed from bearish to bearish weakening. RSI indicator is in the lower part of the neutral territory and it heading north. These factors indicate that the upside trend is forming Last signal: exit from the overbought zone.

2023-08-05 Trend changed from flat and down to linear down.

2023-08-04 Trend pattern changed from расходящийся клин с наклоном вверх to сужающийся канал.

2023-08-04 Signal in Stochastic changed from bullish to bearish. The stochastic indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: main and signal line crossing.

Current temperature: 19.39
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 11
Target Price Mean 16.64
Mean unverified/preliminary 16.64 / 16.64
Target Price Low / High 13.00 / 22.00
Median / STD DEV 17.00 / 2.58
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total None None ActivelyBuy
rsi Sell None ActivelyBuy
macd ActivelyBuy None None
stoch ActivelyBuy None None
ma20 Sell Sell ActivelyBuy
ma50 ActivelyBuy None None
ma100 Sell None ActivelyBuy
Candlestick PatternMarch 6, 2026 Bearish Squeeze Alert - pattern is a made up of three candlesticks. A white candlestick appears on the first day in a uptrend. The second and third days each have lower highs and higher lows than the previous day. Their color is not important. Considered to be a bearish reversal pattern.
ISIN US75943R1023
ceo Dr. Sanjiv K. Patel M.A., M.B.A., M.D., MBBS
Website https://www.relaytx.com
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.